Search

Oxford Biomedica PLC

Aperta

584 -0.34

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

570

Massimo

599

Metriche Chiave

By Trading Economics

Entrata

-16M

-26M

Vendite

-4.8M

73M

EPS

-0.11

Margine di Profitto

-36

Dipendenti

900

EBITDA

-11M

-6.1M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+8.75% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

119M

790M

Apertura precedente

584.34

Chiusura precedente

584

Oxford Biomedica PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 ott 2025, 20:00 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 ott 2025, 23:44 UTC

Discorsi di Mercato

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 ott 2025, 23:37 UTC

Discorsi di Mercato

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 ott 2025, 23:36 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 ott 2025, 23:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

19 ott 2025, 23:09 UTC

Discorsi di Mercato

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 ott 2025, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 ott 2025, 22:30 UTC

Utili

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 ott 2025, 22:18 UTC

Discorsi di Mercato

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 ott 2025, 21:50 UTC

Discorsi di Mercato

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 ott 2025, 21:15 UTC

Discorsi di Mercato

Investors Need to Change Narrative Toward Scales -- Market Talk

19 ott 2025, 19:34 UTC

Acquisizioni, Fusioni, Takeovers

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 ott 2025, 19:34 UTC

Acquisizioni, Fusioni, Takeovers

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 ott 2025, 19:33 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 ott 2025, 19:32 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 ott 2025, 19:32 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 ott 2025, 19:31 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 ott 2025, 19:31 UTC

Acquisizioni, Fusioni, Takeovers

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 ott 2025, 16:29 UTC

Utili

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 ott 2025, 11:14 UTC

Utili

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 ott 2025, 11:14 UTC

Utili

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 ott 2025, 11:14 UTC

Utili

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 ott 2025, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

17 ott 2025, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 ott 2025, 22:15 UTC

Discorsi di Mercato

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 ott 2025, 21:15 UTC

Discorsi di Mercato

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Oxford Biomedica PLC Previsione

Obiettivo di Prezzo

By TipRanks

8.75% in crescita

Previsioni per 12 mesi

Media 639.448 GBX  8.75%

Alto 969.534 GBX

Basso 450.783 GBX

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Oxford Biomedica PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
help-icon Live chat